Dynavax Technologies Corporation is a drug manufacturers-specialty & generic business based in the US. Dynavax Technologies Corporation shares (DVAX) are listed on the NASDAQ and all prices are listed in US Dollars. Dynavax Technologies Corporation employs 311 staff and has a trailing 12-month revenue of around $732.1 million.
Finder Award
SoFi Invest
Robinhood
tastyworks
| Latest market close | $11.84 |
|---|---|
| 52-week range | $7.26 - $17.48 |
| 50-day moving average | $11.62 |
| 200-day moving average | $11.72 |
| Wall St. target price | $23.20 |
| PE ratio | 4.9915 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $2.34 |
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $11.84 from 2023-01-27
| 1 week (2023-01-23) | 2.25% |
|---|---|
| 1 month (2022-12-30) | 11.28% |
| 3 months (2022-10-28) | 0.94% |
| 6 months (2022-07-29) | -17.66% |
| 1 year (2022-01-28) | -6.03% |
|---|---|
| 2 years (2021-01-29) | 87.64% |
| 3 years (2020-01-30) | 137.27% |
| 5 years (2018-01-30) | 16.4 |
Valuing Dynavax Technologies Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Dynavax Technologies Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Dynavax Technologies Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, Dynavax Technologies Corporation shares trade at around 5x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Dynavax Technologies Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $313.2 million.
The EBITDA is a measure of a Dynavax Technologies Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $732.1 million |
|---|---|
| Operating margin TTM | 42.23% |
| Gross profit TTM | $235 million |
| Return on assets TTM | 20.14% |
| Return on equity TTM | 114.48% |
| Profit margin | 44.42% |
| Book value | $3.92 |
| Market capitalisation | $1.5 billion |
TTM: trailing 12 months
We're not expecting Dynavax Technologies Corporation to pay a dividend over the next 12 months.
Dynavax Technologies Corporation's shares were split on a 1:10 basis on 9 November 2014. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Dynavax Technologies Corporation shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Dynavax Technologies Corporation shares which in turn could have impacted Dynavax Technologies Corporation's share price.
Over the last 12 months, Dynavax Technologies Corporation's shares have ranged in value from as little as $7.26 up to $17.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Dynavax Technologies Corporation's is 1.428. This would suggest that Dynavax Technologies Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd. ; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.